Chengdu Institute of Biological Products Co., Ltd. to Strengthen Pharmacovigilance Process using ArisGlobal®'s ARISg™ Solution.
PRINCETON, NJ, March 1, 2016 /CNW/ - ArisGlobal®, a leading provider of software solutions to the life science industry, has announced that Chengdu Institute of Biological Products Co., Ltd. (CDIBP) has selected ARISg™ to strengthen and build a solid foundation for its pharmacovigilance process.
Located in Chengdu, CDIBP (a subsidiary of China National Biotec Group Co., Ltd. (CNBG)) is one of the largest developing and manufacturing bases of vaccines and biological products in China. CDIBP, in partnership with PATH, an international nonprofit focused on improving health, has been working on building a pharmacovigilance database that meets the World Health Organization's requirements to provide affordable vaccines to a broader market.
With the implementation of ARISg™, a safety information management system chosen by life sciences companies worldwide, CDIBP will be able to establish an effective clinical safety and pharmacovigilance system from case data entry to automatic generation of submission-ready adverse event reports that fully support all global regulatory reporting requirements. The system will also be available in the Chinese language to more efficiently support Chinese users.
"It's a very nice experience to work with ArisGlobal®. They provide us with not only their excellent product, but also their leading expertise in pharmacovigilance systems and first class service to meet customer requirements," said Mr. Zhang Lei, International Cooperation Project Manager, Chengdu Institute of Biological Products Co., Ltd.
"We are very pleased that CDIBP has selected ARISg™ for its safety system and will be our first customer in the Chinese Market," said Kazushi Iwai, Business Development Director for North Asia at ArisGlobal KK. "Because of the growing pharmaceutical market in China, combined with a more stringent regulatory environment, meeting an increased demand for expertise in pharmacovigilance practices can be one of the challenges faced by domestic companies and healthcare practitioners. ArisGlobal®'s in-depth knowledge and experience in the pharmacovigilance domain will support CDIBP in implementing and understanding the best practices and requirements that are critically important in drug safety and risk management."
CDIBP's ARISg™ safety system will be implemented by ArisGlobal KK, the Japanese subsidiary of ArisGlobal®, located in Tokyo Japan.
ArisGlobal® (http://www.arisglobal.com) specializes in the delivery of innovative, cloud compliant software solutions that facilitate global drug development and regulatory compliance within the Life Sciences and Healthcare industries. Its comprehensive portfolio supports the entire product life cycle including Clinical Development, Regulatory Affairs, Pharmacovigilance and Medical Communications.
ArisGlobal®'s advanced technology solutions currently empower over 200 drug and device manufacturers, CROs and regulatory agencies to make better and more informed decisions, facilitate compliance, reduce risk and improve operational efficiency. Headquartered in the United States, ArisGlobal® has regional offices in Europe, India and Japan.